These innovative molecules represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://antonphxh991445.ampedpages.com/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide-66048677